Crescent Biopharma, Inc. (CBIO)

NASDAQ: CBIO · Real-Time Price · USD

14.91

+0.79 (5.59%)

Oct 9, 2026, 4:00 PM EDT - Market closed

Crescent Biopharma Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	11.88	10.84	-
Revenue Growth	-	-	-
Gross Profit	11.88	10.84	-
Operating Income	-170.24	-152.63	-68.76
Net Income	-165.12	-153.94	-71.47
Earnings Per Share	-6.03	-12.81	-93.11
EPS Growth	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Investments	171.59	213.19	34.77
Total Debt	1.44	1.64	37.48
Net Cash (Debt)	170.16	211.55	-2.72
Net Cash Growth	-	-	-
Net Cash Per Share	6.21	17.61	-3.54

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Cash Flow	-72.68	-71.53	-25.08
Capital Expenditures	-0.94	-0.92	-
Free Cash Flow	-73.62	-72.45	-25.08
Free Cash Flow Growth	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Gross Margin	100.00%	100.00%	-
Operating Margin	-1432.63%	-1407.53%	-
Pretax Margin	-1372.75%	-1401.16%	-
Profit Margin	-1389.58%	-1419.61%	-
FCF Margin	-619.52%	-668.12%	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Oct '26 Oct 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
PS Ratio	53.70	21.38	-